Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | PSMB1 | P20618 | 4/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.44 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13732452 | 0.96 | HRH3 (0.47) | HRH3KCNH2LTA4HFLT3KDM4E | |
| SCHEMBL13589529 | 0.77 | HRH3 (0.73) | HRH3KCNH2LTA4HKDM4EPSMB1 | |
| SCHEMBL17571469 | 0.77 | KDM4E (0.56) | HRH3LTA4HKDM4EPSMB1PSMB5 | |
| SCHEMBL13731094 | 0.76 | LOX (0.39) | — | |
| SCHEMBL13730672 | 0.76 | EPAS1 (0.38) | — | |
| SCHEMBL18474533 | 0.75 | KDM4E (0.63) | HRH3LTA4HKDM4EPSMB1PSMB5 | |
| SCHEMBL18480195 | 0.75 | LTA4H (0.55) | HRH3LTA4HKDM4EPSMB1PSMB5 | |
| SCHEMBL18474438 | 0.75 | LTA4H (0.55) | HRH3LTA4HKDM4EPSMB1PSMB5 | |
| SCHEMBL17555438 | 0.75 | LTA4H (0.55) | HRH3LTA4HKDM4EPSMB1PSMB5 | |
| SCHEMBL17562439 | 0.74 | KDM4E (0.63) | LTA4HFLT3KDM4EPSMB1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2699543-B1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | INTEGRATIVE RES LAB SWEDEN AB (SE) | 2016-03-02 | — | — | EP | claimed |
| US-9006227-B2 | Modulators of cortical dopaminergic- and NMDA-receptor-mediated glutamatergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2015-04-14 | — | — | US | claimed |
| US-20140128360-A1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | Integrative Research Laboratories Swenden AB (SE) | 2014-05-08 | — | — | US | claimed |
| EP-2699543-A1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | Integrative Research Laboratories Sweden AB (SE) | 2014-02-26 | — | — | EP | claimed |
| WO-2012143337-A1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | NEUROSEARCH A/S (DK) | 2012-10-26 | — | — | WO | claimed |
| EP-2699543-B1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | INTEGRATIVE RES LAB SWEDEN AB (SE) | 2016-03-02 | — | — | EP | disclosed |
| US-9120728-B2 | Modulators of cortical dopaminergic- and NMDA-receptor-mediated glutamatergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2015-09-01 | — | — | US | disclosed |
| US-20150148426-A1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2015-05-28 | — | — | US | disclosed |
| US-9006227-B2 | Modulators of cortical dopaminergic- and NMDA-receptor-mediated glutamatergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2015-04-14 | — | — | US | disclosed |
| US-20140128360-A1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | Integrative Research Laboratories Swenden AB (SE) | 2014-05-08 | — | — | US | disclosed |
| EP-2699543-A1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | Integrative Research Laboratories Sweden AB (SE) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012143337-A1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | NEUROSEARCH A/S (DK) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128360-A1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | GRIN3A, GRIN1, GRIN3B | HRH3 187/4885KCNH2 458/4885LTA4H 2685/4885 |
| US-20150148426-A1 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION | GRIN3A, GRIN1, GRIN3B | HRH3 187/4885KCNH2 458/4885LTA4H 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.